Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$4.60 USD
-0.13 (-2.75%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.61 +0.01 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Inozyme Pharma, Inc. [INZY]
Reports for Purchase
Showing records 61 - 70 ( 70 total )
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Make No Bones About it! Treatment Options Are Needed
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
INZY Looks to Bring 701 to the Clinic in 21
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q20; Start of First-in-Human INZ-701 Studies on Track for Early 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D